TRCT
KYMR icon

Tower Research Capital (TRC)’s Kymera Therapeutics KYMR Stock Holding History

Tower Research Capital (TRC)’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$333K Buy
4,004
+2,742
+217% +$217K 0.01% 1220
2025
Q4 		$98.2K Sell
1,262
-931
-42% -$62.9K ﹤0.01% 1960
2025
Q3 		$124K Sell
2,193
-3,232
-60% -$146K ﹤0.01% 1831
2025
Q2 		$237K Buy
5,425
+2,858
+111% +$98.4K 0.01% 1623
2025
Q1 		$70.3K Sell
2,567
-2,245
-47% -$81.8K ﹤0.01% 1984
2024
Q4 		$194K Buy
4,812
+2,350
+95% +$106K ﹤0.01% 1747
2024
Q3 		$117K Sell
2,462
-10,663
-81% -$471K ﹤0.01% 2112
2024
Q2 		$392K Buy
13,125
+12,421
+1,764% +$430K 0.01% 1534
2024
Q1 		$28.3K Sell
704
-2,049
-74% -$73.3K ﹤0.01% 2700
2023
Q4 		$70.1K Sell
2,753
-3,899
-59% -$69.7K ﹤0.01% 2911
2023
Q3 		$92.5K Buy
6,652
+3,753
+129% +$75.5K ﹤0.01% 2039
2023
Q2 		$66.6K Buy
2,899
+1,146
+65% +$32.8K ﹤0.01% 2342
2023
Q1 		$52K Sell
1,753
-3,646
-68% -$118K ﹤0.01% 2455
2022
Q4 		$135K Sell
5,399
-13,223
-71% -$353K 0.01% 1593
2022
Q3 		$405K Buy
18,622
+7,093
+62% +$187K 0.01% 1304
2022
Q2 		$227K Buy
11,529
+8,363
+264% +$195K 0.01% 1671
2022
Q1 		$134K Sell
3,166
-1,450
-31% -$61.2K ﹤0.01% 2006
2021
Q4 		$293K Buy
4,616
+910
+25% +$53K 0.01% 1492
2021
Q3 		$218K Buy
3,706
+1,986
+115% +$115K 0.01% 1738
2021
Q2 		$83K Buy
1,720
+236
+16% +$10.2K ﹤0.01% 2574
2021
Q1 		$58K Buy
1,484
+734
+98% +$44.2K ﹤0.01% 2994
2020
Q4 		$47K Sell
750
-220
-23% -$10.7K ﹤0.01% 3182
2020
Q3 		$31K Buy
+970
New +$29.6K ﹤0.01% 3715

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Tower Research Capital (TRC)'s KYMR Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Kymera Therapeutics (KYMR) stake by 217% in Q1 2026, buying an estimated $217K and bringing the position to 4,004 shares worth $333K. The position accounts for 0.01% of the portfolio, ranked #1220.

Tower Research Capital (TRC) first reported a position in KYMR in Q3 2020 and has held it in 23 quarters since. The position peaked at $405K in Q3 2022. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Tower Research Capital (TRC) held 4,004 shares of Kymera Therapeutics worth $333K as of Q1 2026.
  • Tower Research Capital (TRC) bought 2,742 Kymera Therapeutics shares in Q1 2026, an estimated $217K.
  • Kymera Therapeutics made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1220 holding.
  • Tower Research Capital (TRC) first reported a position in Kymera Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Tower Research Capital (TRC)'s Kymera Therapeutics position peaked at $405K in Q3 2022.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.